197 results about "Anti sense" patented technology

Plants, particularly cereal plants, which have improved ability to synthesise starch at elevated or lowered temperatures and / or to synthesise starch with an altered fine structure are produced by inserting into the genome of the plant (i) a gene(s) encoding a form of an enzyme of the starch or glycogen biosynthetic pathway, particularly soluble starch synthase and / or branching enzyme and / or glycogen synthase, which display an activity which continues to increase over a temperature range over which the activity would normally be expected to decrease, and / or (ii) a gene(s) encoding sense and anti-sense constructs of enzymes of the starch biosynthetic pathway, particularly soluble starch synthase and / or branching enzyme and / or glycogen synthase, which alters the natural ratios of expression of the said enzymes or inserts enzymes with special structural characteristics which alter the natural branching pattern in starch.

By this invention, modification of the fatty acid composition of a plant seed may be achieved as a result of the activity of a DNA sequence foreign to the plant species to be modified. In particular, it has been found that a plant oil having a modified fatty acid composition can be obtained upon the expression of genes derived from plants of different species than the host plant, upon the expression of genes derived from bacteria, and from the transcription of anti-sense sequences which are complementary to endogenous genes of the plant host cell. In a preferred embodiment, transcription of the fatty acid modifying foreign DNA sequence is restricted to the developing seed tissues.

A therapeutic and / or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.

The present invention relates to a single-chain circular RNA having a sustained or slow-releasing RNA interference effect, characterized in that the single-chain circular RNA comprises a sense strand sequence, an antisense strand sequence complementary to the sense strand sequence, identical or different two loop sequences between the sense strand and the antisense strand, connecting both strands, wherein the sense strand and the antisense strand are paired to form a stem.

By this invention, modification of the fatty acid composition of a plant seed may be achieved as a result of the activity of a DNA sequence foreign to the plant species to be modified. In particular, it has been found that a plant oil having a modified fatty acid composition can be obtained upon the expression of genes derived from plants of different species than the host plant, upon the expression of genes derived from bacteria, and from the transcription of anti-sense sequences which are complementary to endogenous genes of the plant host cell. In a preferred embodiment, transcription of the fatty acid modifying foreign DNA sequence is restricted to the developing seed tissues.

Bicyclonucleoside analogues which exhibit anti-AIDS activity and intermediates to produce oligonucleotide analogues which have anti-sense or anti-gene activity as well as in vivo stability. Compounds of the following formula (1) or their pharmaceutically acceptable salts.wherein R1 represents a hydrogen atom or a protecting group for a hydroxy group, R2 represents an azido group or an optionally protected amino group or the like, B represents a purin-9-yl or a 2-oxo-1,2-dihydropyrimidin-1-yl group, which are optionally substituted with substituents selected from the group consisting of a halogen atom, an alkyl group having 1–6 carbon atoms, a hydroxy group, a mercapto group and an amino group.

The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.

Assays and methods including mobile tagged single stranded nucleic acid reagents pre-loaded on an analysis device, which are preferably tagged, but not labeled and are complementary to a strand (preferably the anti-sense strand in double stranded DNA targets) of the target nucleic acid. The assay also includes a running buffer that includes a dye or other detectable label that nonspecifically binds only to double stranded nucleic acids. In addition, the analysis device includes a detection zone including one or more test zones that have an immobilized tag that binds to the tag on the mobile nucleic acid reagent.

The present invention provides systems and methods for production of activatable diazo-derivatives for use in labeling nucleotides. Labeling nucleotides is accomplished by contacting a stable hydrazide derivative of a detectable moiety with an activating polymer reagent which is used to directly label the nucleotide sample. Labeling occurs on the phosphate backbone of the nucleotide which does not perturb hybridization of the labeled nucleotide with its anti-sense strand. Since the method involves direct labeling, all types of nucleotides can be labeled without prior amplification or alteration.

Several engineered U6 and H1 promoters have been discovered. Using these engineered U6 and H1 promoters, anti-sense or siRNA can be expressed in a regulated way. In the absence of an inducer, the antisense or siRNA is not expressed by the promoters. In the presence of an inducer, the antisense or siRNA can be expressed by the promoters.

Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other LNA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

The invention discloses a RNA interference preparation used for treating viral hepatitis B. The RNA interference preparation comprises one or more sense strands and one or more antisense strands, wherein one or more polynucleotide strands are complementary with one or more regions of HBV RNA. An iNA is an iNAs having a structure of double stands. The double strands have structures of linear, loop, similar-loop, hairpin-type, stem-loop, unidirectional or bidirectional. The RNA interference preparation provided by the invention can be used for treating viral hepatitis B.

By this invention, compositions and methods of use of plant desaturase enzymes, especially Δ-9 desaturases, are provided. Of special interest are methods and compositions of amino acids and nucleic acid sequences related to biologically active plant desaturases as well as sequences, especially nucleic acid sequences, which are to be used as probes, vectors for transformation or cloning intermediates. Biologically active sequences may be found in a sense or anti-sense orientation as to transcriptional regulatory regions found in various constructs.

This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK / SPINK / PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and / or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and / or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and / or p21 gene expression as well as methods for increasing the chemo and / or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.

The present invention relates to compositions for use in raising or lowering the level of LIPG polypeptide in a patient. Embodiments of the composition include compositions comprising: an anti-sense nucleic acid; a neutralizing antibody; an intracellular binding protein; an inhibitor which inhibits the enzymatic activity of LIPG polypeptide; an inhibitor which inhibits the expression of LIPG gene; a ribozyme; an LIPG polypeptide; an enhancer which increases the enzymatic activity of LIPG polypeptide; or an enhancer which increases the expression of LIPG gene. The invention relates also to methods for using the above compositions.In addition, the invention relates to a method for diagnosing a predisposition to lower cholesterol, a method for determining whether a test compound can inhibit the enzymatic reaction between LIPG polypeptide and HDL cholesterol, and methods for determining whether a test compound can enhance the enzymatic reaction between LIPG polypeptide and LDL or VLDL cholesterol.

The invention provides a long non-coding RNA (long non-coding RNA, 1ncRNA)-incRNA-HN3 sequence relevant to human melanoma cells, and an RNA interference (RNA interference, RNAi) target spot sequence, a short-hairpin RNA (short-hairpin RNA, shRNA) sequence, an shRNA coded small molecule interference RNA (small interference RNA, siRNA), a coding shRNA coding strand and an anti-sense strand DNA sequence, coding shRNA recombinant plasmids of the long non-coding RNA sequence, and the invention relates to the applications of the long non-coding RNA sequence for preparing reagents for diagnosing melanoma diseases and drugs for treating the melanoma diseases.

The present invention relates to the isolation, purification, characterization and use of a mitochondrial pyruvate dehydrogenase kinase (PDHK) gene [SEQ ID NO:1](pYA5; ATCC No 209562) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DNA of the stated sequence and relates to methods of regulating fatty acid synthesis, seed oil content, seed size / weight, flowering time, vegetative growth, respiration rate and generation time using the gene and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of SEQ ID NO:1; or a part of SEQ ID NO:1 characterized in that said sequence has been introduced into an antisense or sense orientation, and a method of producing such plants and plant seeds. The invention also relates to substantially homologous DNA sequences from plants encoding proteins with deduced amino acid sequences of 25% or greater identity, and 50% or greater similarity, isolated and / or characterized by known methods using the sequence information of SEQ ID NO:1, and to parts of reduced length that are still able to function as inhibitors of gene expression by use in an anti-sense, co-suppression or other gene silencing technologies.

The invention provides small interfering nucleic acid of which sequences are as follows: the sequence of the sense strand is 5'-CCUUGAGGCAUACUUCAAAdTdT-3' and the sequence of the anti-sense strand is 5'-UUUGAAGUAUGCCUCAAGGdTdT-3'. The small interfering nucleic acid has the modifications shown from A1 to A5. The invention also provides a medical composite used for preventing and / or curing hepatitis B and the medical composite contains the small interfering nucleic acid provided by the invention and uses the nucleic acid as the active component. The invention also provides the applications of the small interfering nucleic acid in preparations of medicines for preventing and / or curing hepatitis B. Through the specific modifications, the aim of increasing the serum stability of the small interfering nucleic acid can be achieved under the condition of only introducing a small amount of modifications, thus the potential cytotoxicity of the modified small interfering nucleic acid molecule can be reduced and the influence on the biological activity can be lowered.

The invention relates to promoters of the genes glutamate dehydrogenase, beta-acetylhexosaminidase and gamma-actin and their use in systems of expression, secretion and anti-sense of filamentary fungi. The invention also relates to the use of the promoters of the genes which code: (I) glutamate dehydrogenase NADP depending (EC.1.4.1.4) of Penicillium chrysogenum, (II) gamma-N-actylhexosaminidase (EC.3.2.1.52) of Penicillium chrysogenum and (III) gamma-actin of Penicillium chrysogenum and Acrimonium chrysogenum, which can be used for the construction of potent vectors of expression and secretion useful both for P. chrysogenum and for A. chrysogenum and related species. These promoters can also be used for blocking the genic expression through anti-sense construction. Under the control of the above mentioned promoters, it is possible to conduct the expression of other genes in filamentary fungi, thereby increasing the production of antibiotics and / or proteins inherent to the same.

A method of amplifying RNA to obtain RNA molecules that are predominantly in the sense orientation and essentially devoid of RNA molecules that are in the anti-sense orientation. A method of transfecting antigen presenting cells with a composition comprising sense RNA encoding immunogenic antigens and essentially devoid of antisense RNA and dsRNA is also provided as well as dendritic cells prepared according to the method.

The invention discloses a method for constructing a tandem expression small interfering RNA recombinant lentiviral vector. The method comprises the following steps of: (1) constructing the siRNA recombinant lentiviral vector with single target spot: a, chemically synthesizing an oligonucleotide chain; b, annealing a sense chain and an anti-sense chain; and c, connecting an annealing fragment to the vector; (2) constructing the siRNA recombinant lentiviral vector with double target spots: a, amplifying a U6 / H1-siRNA expression frame from the siRNA recombinant lentiviral vector with single target spot by utilizing the PCR; b, connecting the expression frame to the siRNA recombinant lentiviral vector with single target spot undergoing enzyme digestion by the XhoI; and c, performing the enzymedigestion, identification and screening of the clone forwardly inserted in the expression frame; and (3) constructing the siRNA recombinant lentiviral vector with multiple target points in tandem connection: inserting the U6 / H1-siRNA expression frame in the siRNA recombinant lentiviral vector with double target spots to construct the siRNA recombinant lentiviral vector with triple target spots, and obtaining the siRNA recombinant lentiviral vector with multiple target points in tandem connection by repeating the step. The construction method is suitably used for the expression of the siRNA with multiple target genes as well as the research on the multiple target genes which are silent for a long time.

By means of plant gene engineering, primer is designed from No. 901 base to No. 1338 base inside the fertility relevant gene, 438 bp sequence is amplified as anti-sense gene segment and introduced into plant chromosome to obtain regenerative plant and artificial male sterile common Chinese cabbage and core. The said method is suitable for rape genus plants and may be used in fast constituting the male sterility line of different Chinese cabbage and similar vegetable crops without the limitation similar to that of seeking natural sterile source. The present invention opens one new way the wide application of plant gene engineering technology in agricultural production.